On one hand, as an ARB, telmisartan rapidly and continuously reduces the level of plasma C-reactive protein in hospitalized COVID-19 patients and telmisartan treatment can shorten the hospitalization time of sufferers (Rothlin et al., 2021). The gene discussed is CRP; the disease is COVID-19.